Michael Perry

Michael S.
Perry is Chairman at 7 Hills Pharma LLC since 2022.
Dr. Perry is Lead Independent Director at Arrowhead Pharmaceuticals, Inc. since 2011.
Dr. Perry is Director at Rosetta Capital Ltd. since 2017.
Dr. Perry is Director at Gamida Cell, Inc. Dr. Perry is Venture Partner at Bioscience Managers Pty Ltd. since 2020.
Former roles include President & Chief Executive Officer at Systemix, Inc. from 1997 to 2000; President & Chief Executive Officer at Pharsight Corp.
from 2002 to 2003; Chairman & Chief Executive Officer at Extropy Pharmaceuticals, Inc. from 2003 to 2005; President & Chief Executive Officer at Genetic Therapy, Inc. from 1994 to 1997; Chief Executive Officer & Non-Executive Director at AVITA Medical Pty Ltd. from 2017 to 2022; Chairman at Xeno Transplants Corp.; Director-Regulatory Affairs at Schering-Plough Corp.
from 1989 to 1991; Independent Director at AmpliPhi Biosciences Corp.
from 2005 to 2019; Director at BioTransplant, Inc.; Independent Director at Gamida Cell Ltd. from 2017 to 2021; Independent Director at Armata Pharmaceuticals, Inc. from 2019 to 2020; Non-Executive Director at AVITA Medical, Inc. in 2022; President, Chief Executive & Technology Officer at Poniard Pharmaceuticals, Inc. from 2011 to 2012; Vice President-Regulatory Affairs at Syntex Corp.; Chief Development Officer at VIA Pharmaceuticals, Inc. from 2004 to 2008; Chief Scientific Officer-Global Business & SVP at Novartis AG from 2016 to 2017; Venture Partner at Bay City Capital LLC from 2004 to 2012; Chief Scientific Officer-Cell & Gene Therapy Unit at Novartis Pharmaceuticals Corp.
from 2014 to 2017; Global Head-Research & Development at Baxter BioScience Corp.
from 2000 to 2002; Vice President-Regulatory Affairs at Sandoz Pharmaceuticals Corp.
from 1994 to 1997.
Education includes undergraduate and doctorate degrees from the University of Guelph, a graduate degree from Harvard Business School, and a doctorate from Ontario Veterinary College.